Tarix announced enrollment in its Phase 2 study of TXA127 to enhance the engraftment process in patients receiving a stem cell transplant. This trial is a double-blind, placebo-controlled multicenter study that will evaluate the safety and efficacy of TXA127 in the acceleration of engraftment following autologous peripheral blood stem cell transplant in patients with Hodgkin’s or non-Hodgkin’s lymphomas or multiple myeloma undergoing limited reinfusion of CD34+ cells. The study is expected to enroll a total of 74 patients at eight sites in the U.S.
TXA127 is a pharmaceutical grade formulation of a naturally occurring peptide known to stimulate early hematopoietic precursor cells in the bone marrow.
For more information visit www.tarixpharma.com.